AstraZeneca’s stock underperforms EU pharma peers by 10% in 6 months
Resolves: AstraZeneca’s stock price underperforms the EU pharma peer index (as defined by a basket of large European pharmaceutical companies) by 10% or more from 2026-07-11 to 2027-01-11.
user-generated· price
AstraZeneca’s stock underperforms EU pharma peers by 10% in 6 months
Market overview
AstraZeneca’s recent trial failure for Wainua has eroded investor confidence in its pipeline premium. If the stock underperforms the EU pharma peer group by 10% or more by January 2027, it would signal broader skepticism about its long-term growth story.
price prediction market
- Implied probability (Yes)
- 72%
- Closes
- 2027-01-11
About this prediction
Resolution criteria
AstraZeneca’s stock price underperforms the EU pharma peer index (as defined by a basket of large European pharmaceutical companies) by 10% or more from 2026-07-11 to 2027-01-11.
Source: user-generated
More price markets
- Brent Crude Oil Falls Below $80 by November 2026 — 65% Yes
- Netflix drops ad-tier pricing by 20% in 2027 — 65% Yes
- Ariana Grande's hiatus reduces ticket resale prices — 68% Yes
- China AI IPO index gains 15% in Q4 2026 — 60% Yes
- Turkish lira depreciates beyond 38 TRY/USD by end-2026 — 68% Yes
- Netflix stock drops below $550 by end of 2026 — 68% Yes
- Coinbase stock exceeds $300 by end of June 2026 — 68% Yes
- Sidechat's valuation drops below $100M by 2026-11-15 due to Fizz lawsuit fallout — 68% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…